NCT04446377View on ClinicalTrials.gov

A Study of LAM-002A for the Prevention of Progression of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

March 24, 2021

Study Completion Date

April 19, 2021

Conditions
COVID-19 Disease
Interventions
DRUG

Apilimod Dimesylate Capsule

LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.

OTHER

Placebo

Microcrystalline cellulose in Swedish orange, Size 0 capsules

Trial Locations (1)

06510

Yale University, New Haven

Sponsors
All Listed Sponsors
collaborator

Yale University

OTHER

lead

OrphAI Therapeutics

INDUSTRY

NCT04446377 - A Study of LAM-002A for the Prevention of Progression of COVID-19 | Biotech Hunter | Biotech Hunter